Market closed
Sarepta Therapeutics/$SRPT
Sarepta Therapeutics shares are trading lower after the EMA halted all studies of its gene therapy Elevidys for Duchenne muscular dystrophy.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,372
Website
SRPT Metrics
BasicAdvanced
$5.7B
25.05
$2.34
0.79
-
Price and volume
Market cap
$5.7B
Beta
0.79
52-week high
$173.25
52-week low
$57.14
Average daily volume
2.2M
Financial strength
Current ratio
4.201
Quick ratio
2.74
Long term debt to equity
87.03
Total debt to equity
87.899
Interest coverage (TTM)
11.86%
Management effectiveness
Return on assets (TTM)
3.77%
Return on equity (TTM)
19.71%
Valuation
Price to earnings (TTM)
25.047
Price to revenue (TTM)
2.93
Price to book
3.72
Price to tangible book (TTM)
3.78
Price to free cash flow (TTM)
-15.797
Growth
Revenue change (TTM)
52.97%
Earnings per share change (TTM)
-140.34%
3-year revenue growth (CAGR)
39.42%
3-year earnings per share growth (CAGR)
-23.14%
What the Analysts think about SRPT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
SRPT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SRPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SRPT News
AllArticlesVideos
$SRPT
NaN%INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Accesswire·12 hours ago
$SRPT
NaN%Sarepta halts three studies testing gene therapy for muscle disorder
Reuters·13 hours ago
$SRPT
NaN%Sarepta Therapeutics Provides Update on ELEVIDYS
Business Wire·13 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $5.7B as of April 05, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 25.05 as of April 05, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
